JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, H. B.
Right arrow Articles by Choe, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H. B.
Right arrow Articles by Choe, K. W.
Journal of Clinical Microbiology, June 2003, p. 2279-2281, Vol. 41, No. 6
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.6.2279-2281.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea

Hong Bin Kim,1 Wan Beom Park,1 Ki Deok Lee,1 Young Joo Choi,1 Sang Won Park,1 Myoung-don Oh,1,2* Eui-Chong Kim,2,3 and Kang Won Choe1,2

Departments of Internal Medicine,1 Laboratory Medicine, Seoul National University College of Medicine,3 Clinical Research Institute, Seoul National University Hospital, Seoul 110-744, Republic of Korea2

Received 21 January 2003/ Returned for modification 18 February 2003/ Accepted 6 March 2003


   ABSTRACT
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Methicillin-resistant Staphylococcus aureus (MRSA) accounts for more than 70% of S. aureus isolates from tertiary hospitals in Korea. Clinical isolates of S. aureus were collected from eight provincial, university-affiliated hospitals during the period from June 1999 to January 2001 for nationwide surveillance. All isolates were screened for reduced susceptibility to vancomycin by using brain heart infusion agar containing 4 µg of vancomycin per milliliter. Population analysis and the determination of the MIC of vancomycin were done for the isolates which grew on the screening agar plates. Of 682 total isolates, MRSA accounted for 64% (439 of 682). Of 27 (4%) isolates that grew on the screening agar plates, none showed the heteroresistance phenotype. No strains with reduced susceptibility to vancomycin were identified.


   INTRODUCTION
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Staphylococcus aureus is one of the most important pathogens, causing severe morbidity and fatal infections. The rapid evolution of antibiotic resistance in S. aureus is of considerable concern. Since the first isolation of methicillin-resistant S. aureus (MRSA) in the United Kingdom in 1961 (17), the prevalence of MRSA increased rapidly worldwide, and glycopeptide antibiotics have been widely relied upon to treat MRSA infections. In 1996, the first documented infection caused by S. aureus with reduced susceptibility to vancomycin (vancomycin-intermediate S. aureus [VISA]) was reported in Japan (10). Thereafter, about 20 cases (28) of VISA infection have been reported in several countries, including Korea (20). Furthermore, 2 isolates of fully vancomycin-resistant S. aureus were documented in the United States during 2002 (4, 5).

In addition to VISA and vancomycin-resistant S. aureus, another type of vancomycin resistance called hetero-VISA (hVISA), has been described by Hiramatsu et al. (8). This strain is susceptible to vancomycin but contains a subpopulation, at a frequency of 10-6 or higher with a MIC of vancomycin of more than 4 µg per milliliter. The potential importance of hVISA is that it may be associated with treatment failure (8, 30, 31) and a precursor of VISA (15, 25). Although a number of studies have been undertaken to determine the prevalence of hVISA, reported frequencies have ranged from 0 to 20% (2, 6, 8, 14, 16, 19, 22, 24, 26, 32), depending on the definitions and methods employed for screening and confirmation.

The prevalence of methicillin resistance is known to be more than 70% among S. aureus isolates from tertiary hospitals in Korea (21). Considering the high prevalence of MRSA and the increased use of vancomycin, the development of vancomycin resistance in clinical strains seems likely to occur. To date, the existence of VISA or hVISA strains in countries with a high prevalence of MRSA has been rarely studied. In this study, we conducted a nationwide survey to investigate the prevalences of VISA and hVISA.

(Presented in part at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 16 to 19 December, 2001.)


   MATERIALS AND METHODS
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Bacterial isolates. Clinical S. aureus isolates were collected from eight university-affiliated hospitals, each hospital representing one of eight provinces in South Korea. From June 1999 to January 2001, each participating hospital sent consecutive isolates identified as S. aureus, ranging from 62 to 99 isolates per hospital. Only one isolate per patient was included in the study. Upon receipt, isolates were subcultured onto blood agar to ensure purity and identification. Initial confirmation of S. aureus was based on colony morphology and agglutination test with PS LATEX (Eiken Chemical, Tokyo, Japan). If necessary, further confirmatory tests were done with a Vitek system (bioMerieux, Durham, N.C.). All isolates were immediately stored at -70°C until required. Mu50 (VISA strain) and Mu3 (hVISA strain), kindly provided by Keiichi Hiramatsu, were used as controls.

Screening for VISA and hVISA. To screen isolates with reduced susceptibility to vancomycin, original isolates or frozen stocks were streaked onto blood agar plates. After overnight incubation, a few colonies were inoculated into tryptic soy broth. A suspension grown overnight in tryptic soy broth equivalent to a 0.5 McFarland standard (108 CFU/ml) was prepared in 0.9% saline. Then, 10 µl (106 CFU) of the suspension was spread onto brain heart infusion agar (Becton Dickinson, Sparks, Md.) containing 4 µg of vancomycin/ml (BHI-V4). The plates were incubated for 48 h at 37°C, and the cell growth was inspected at 24 and 48 h (7). If confluent growth was apparent within 24 h, similar to that of Mu50, the strain was considered a potential VISA strain. If a countable (1 to 30) number of colonies was apparent within 48 h, similar to Mu3, the strain was designated as a possible hVISA strain. If cell growth was not apparent within 48 h, the strain was considered susceptible to vancomycin (5). Whenever screening tests were repeated, BHI-V4 plates were newly prepared and the positive controls were used. The isolates were passaged no more than twice on nonselective medium.

Population analysis. Any isolates that grew on BHI-V4 were subjected to population analysis, as previously described (27). After diluting overnight cultures to a 0.5 McFarland standard, 50 µl of the cell suspension and its serial diluents were spread onto BHI agar plates containing vancomycin concentrations in the range 1 to 10 mg/liter with 1-mg/liter increments. The plates were incubated at 37°C for 48 h, and the number of colonies was counted.

Determination of MIC. MICs of oxacillin and vancomycin were determined by the broth microdilution method with cation-adjusted Muller-Hinton broth (Becton Dickinson), according to the National Committee for Clinical Laboratory Standards guidelines (23). Quality control was performed by testing with S. aureus ATCC 29213.


   RESULTS
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A total of 682 isolates were collected from eight tertiary hospitals: 199 (29%) from pus, 152 (22%) from respiratory specimens, 137 (20%) from blood, and 38 (6%) from urine.

The overall prevalence of MRSA was 64% (439 of 682), which varied from 55 to 74% for hospitals and from 48 to 92% by specimen type.

In total, 27 (4%) isolates (21 MRSA and 6 methicillin-susceptible S. aureus isolates) grew on BHI-V4 after 48 h of incubation, but none possessed the heteroresistance phenotype on population analysis. Vancomycin MICs ranged from 1 to 2 µg/ml (Fig. 1).



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 1. Result of the nationwide surveillance study for S. aureus with reduced susceptibility to vancomycin. Among 682 S. aureus isolates from eight university-affiliated hospitals, 27 (4%) isolates grew on BHI-V4 agar after incubation for 48 h at 37°C. None revealed the heteroresistance phenotype upon population analysis. MICs of vancomycin, determined by the broth microdilution method, ranged from 1 to 2 µg/ml.

 

   DISCUSSION
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We examined the prevalence of S. aureus with reduced susceptibility to vancomycin in hospitals with a high prevalence of MRSA. Although several hVISA or VISA isolates were expected to be found, no isolates with reduced susceptibility to vancomycin were detected.

In this study, population analysis was used as the standard method for the confirmation of hVISA instead of the method described by Hiramatsu et al. (8). Studies examining the prevalence of hVISA defined by the existence of a resistant subpopulation of cells have not generally been well standardized, which presumably is reflected by reported differences in the prevalence of hVISA. While many different methods have been evaluated (12, 14, 18, 29, 32, 33), population analysis profiling is presumed to be the only reliable way of confirming the heterogeneity of vancomycin susceptibility (13, 28). We also screened the isolates by using another method based on the antagonism of vancomycin and beta-lactam for hVISA (32; H. Hanaki, S. Ohkawa, Y. Yoko, T. Hashimoto, and K. Hiramatsu, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-132, 1998). Briefly, after the prepared bacterial solution, adjusted to 1.0 McFarland turbidity, was swabbed on the Mu3 agar (Becton Dickinson) or BHI-V4, aztreonam (30 µg), cefixime (5 µg), and cefminox (30 µg) disks were applied. None revealed a dense growth around beta-lactam disks after incubation at 37°C for 24 h (data not shown).

Our result differs from those of other studies; for example, hVISA strains represented 5 to 22% of the MRSA isolates in Japanese university hospitals (8) and 8.2% of the 85 MRSA strains studied in Germany by Geisel et al. (6). In contrast, hVISA strains were rarely detected in England and Wales (2), the United States (26), or a Korean university hospital (19). Even within the same countries, there have been conflicting results on the prevalence of hVISA (8, 16). These results suggest that several factors, such as the characteristics of bacterial isolates, the epidemiologic situation of antibiotic resistance, and the genetic background of clinical S. aureus isolates, might also contribute to the development of vancomycin resistance.

In this study, we collected isolates of S. aureus from the nonselective population. Studies involving a selected population, such as patients in intensive care units (18) and orthopedic patients with surgical-site MRSA infections (1), reported higher prevalence rates of hVISA. We believe that differences between the study populations may have lead to the variable results. In addition, hVISA appears to be more common in Hong Kong (30) and Germany (6) than in the United Kingdom (2, 32), the United States (14, 26), and Italy (22), which is suggestive of regional differences.

It was previously reported that some VISA isolates belonged to the same clonotype (11), which indicates that some clonotypes have a tendency to acquire vancomycin resistance compared with others. Although the isolates from Korea, Japan, and the United States were known to share clonotype II-A (9), our study indicates the low prevalence of hVISA and VISA. This could imply that the clonotype per se, though a predisposing factor, may not be sufficient for the development of reduced susceptibility to vancomycin.

It is possible that the resistance phenotype was not detected in some isolates with unstable vancomycin resistance because of resistance reversion during transit on nonselective medium (3). But this phenomenon has a stepwise nature of reversion during serial passage. To prevent this reversion, we plated the isolates no more than twice on routine nonselective medium. Therefore, resistance reversion is not a likely explanation for the low prevalence of hVISA observed in the present study.

Despite the high prevalence of MRSA in tertiary hospitals, our investigation found no evidence of the dissemination of any hVISA or VISA strain in Korea.


   ACKNOWLEDGMENTS
 
This study was supported by a grant (HMP-99-M-04-0002) from the Ministry of Health and Welfare, Seoul, Korea.

We thank S. H. Koo (Chungnam National University), S. J. Kim (Gyeongsang National University), S. Kiem (Sungkyunkwan University), D. H. Shin (Chonnam National University), H. S. Shin (Chungbuk National University), S. H. Lee and C. Chang (Pusan National University), and H. S. Lee (Chonbuk National University) for collecting S. aureus isolates. We also thank Keiichi Hiramatsu (Juntendo University, Tokyo, Japan) for providing the Mu50 and Mu3 strains.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yeongun-dong, Chongro-gu, Seoul 110-744, Republic of Korea. Phone: 82-2-760-2945. Fax: 82-2-762-9662. E-mail: mdohmd{at}snu.ac.kr. Back


   REFERENCES
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.[CrossRef][Medline]
  2. Aucken, H. M., M. Warner, M. Ganner, A. P. Johnson, J. F. Richardson, B. D. Cookson, and D. M. Livermore. 2000. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 46:639-640.[Free Full Text]
  3. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277.[Abstract/Free Full Text]
  4. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.[Medline]
  5. Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. Rep. 51:902.[Medline]
  6. Geisel, R., F. J. Schmitz, L. Thomas, G. Berns, O. Zetsche, B. Ulrich, A. C. Fluit, H. Labischinsky, and W. Witte. 1999. Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area. J. Antimicrob. Chemother. 43:846-848.[Free Full Text]
  7. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Resist. Updat. 1:135-150.
  8. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.[CrossRef][Medline]
  9. Hiramatsu, K., L. Cui, M. Kuroda, and T. Ito. 2001. The emergence of evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 9:486-493.[CrossRef][Medline]
  10. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.[Free Full Text]
  11. Hiramatsu, K., T. Ito, and H. Hanaki. 1999. Mechanism of methicillin and vancomycin resistance in Staphylococcus aureus. Clin. Infect. Dis. 5:221-242.
  12. Howe, R. A., M. Wooten, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 1999. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 44:675-678.[Abstract/Free Full Text]
  13. Howe, R. A., M. Wooten, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 1999. Heterogeneous resistance to vancomycin in Staphylococcus aureus. J. Antimicrob. Chemother. 45:129-134.
  14. Hubert, S. K., J. M. Mohammed, S. K. Fridkin, R. P. Gaynes, J. E. McGowan, and F. C. Tenover. 1999. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J. Clin. Microbiol. 37:3590-3593.[Abstract/Free Full Text]
  15. Hussain, F. M., S. Boyle-Vavra, P. B. Shete, and R. S. Daum. 2002. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. 186:661-667.[CrossRef][Medline]
  16. Ike, Y., Y. Arakawa, X. Ma, K. Tatewaki, M. Nagasawa, H. Tomita, K. Tanimoto, and S. Fujimoto. 2001. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J. Clin. Microbiol. 39:4445-4451.[Abstract/Free Full Text]
  17. Jevons, M. P. 1961. "Celbenin"-resistant staphylococci. BMJ 1:124-126.
  18. Jung, S. I., S. Kiem, N. Y. Lee, Y. S. Kim, W. S. Oh, H. L. Cho, K. R. Peck, and J. H. Song. 2002. One-point population analysis and effect of osmolarity on detection of hetero-vancomycin resistant Staphylococcus aureus. J. Clin. Microbiol. 40:1493-1495.[Abstract/Free Full Text]
  19. Kim, M. N., S. H. Hwang, Y. J. Pyo, H. M. Mun, and C. H. Pai. 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. 40:1376-1380.[Abstract/Free Full Text]
  20. Kim, M. N., C. H. Pai, J. H. Woo, J. S. Ryu, and K. Hiramatsu. 2000. Vancomycin-intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38:3879-3881.[Abstract/Free Full Text]
  21. Lee, K., C. L. Chang, N. Y. Lee, H. S. Kim, K. S. Hong, H. C. Cho, and Korean Nationwide Surveillance of Antimicrobial Resistance Group. 2000. Korean nationwide surveillance of antimicrobial resistance of bacteria in 1998. Yonsei Med. J. 41:497-506.[Medline]
  22. Marchese, A., G. Balistreri, E. Tonoli, E. A. Debbia, and G. C. Schito. 2000. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J. Clin. Microbiol. 38:866-869.[Abstract/Free Full Text]
  23. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  24. Reverdy, M. E., S. Jarraud, S. Bobin-Dubreux, E. Burel, P. Girardo, G. Lina, F. Vandenesch, and J. Etienne. 2001. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clin. Microbiol. Infect. 7:267-272.[CrossRef][Medline]
  25. Sieradzki, K., R. B. Roberts, S. W. Haber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523.[Free Full Text]
  26. Tallent, S. M., T. Bischoff, M. Climo, B. Ostrowsky, R. P. Wenzel, and M. B. Edmond. 2002. Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J. Clin. Microbiol. 40:2249-2250.[Abstract/Free Full Text]
  27. Tomasz, A., S. Nachman, and H. Leaf. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124-129.[Abstract/Free Full Text]
  28. Walsh, T. R., and R. A. Howe. 2002. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56:657-675.[CrossRef][Medline]
  29. Walsh, T. R., A. Bolmstrom, A. Qwarnstrom, P. Ho, M. Wootton, R. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.[Abstract/Free Full Text]
  30. Wong, S. S. Y., P. L. Ho, P. C. Y. Woo, and K. Y. Yuen. 1999. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin. Infect. Dis. 29:760-767.[Medline]
  31. Wong, S. S. Y., T. K. Ng, W. C. Yam, D. N. C. Tsang, P. C. Y. Woo, S. K. S. Fung, and K. Y. Yuen. 2000. Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diagn. Microb. Infect. Dis. 36:261-268.[CrossRef][Medline]
  32. Woodford, N., M. Warner, and H. M. Aucken. 2000. Vancomycin resistance among epidemic strains of methicillin-resistant Staphylococcus aureus in England and Wales. J. Antimicrob. Chemother. 45:258-259.[Free Full Text]
  33. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.[Abstract/Free Full Text]

Journal of Clinical Microbiology, June 2003, p. 2279-2281, Vol. 41, No. 6
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.6.2279-2281.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, H. B.
Right arrow Articles by Choe, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H. B.
Right arrow Articles by Choe, K. W.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS